Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiac implantable electronic devices and radiation therapy: long-term outcomes.

European heart journal·2026

Same author

Cardiovascular Safety of Hormonal Contraception: Method-Specific Risks and Clinical Implications.

Medical sciences (Basel, Switzerland)·2026

Same author

The Road to Hell Is Paved With Plugged Ports-Leadless EGM Findings and Their Potential Clinical Implications.

Journal of cardiovascular electrophysiology·2026

Same author

Impact of Anabolic-Androgenic Steroid Abuse on the Cardiovascular System: Molecular Mechanisms and Clinical Implications.

International journal of molecular sciences·2025

Same author

Preoperative Albumin-Bilirubin (ALBI) Score Is the Strongest Predictor of Mortality After LVAD Implantation.

Biomedicines·2025

Same author

Copeptin, Routine Laboratory Parameters, and Ischemic Etiology of Heart Failure Predict Outcomes in Elderly Patients with Decompensated Heart Failure.

Biomedicines·2025

Search research articles

Related Experiment Video

Updated: Dec 9, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Adiponectin in heart failure.

Hubert Mado¹, Wioletta Szczurek², Mariusz Gąsior³

¹Student Scientific Society, 3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.

Future Cardiology

|September 11, 2020

Summary

Adiponectin, a hormone from fat tissue, typically benefits heart health. However, higher levels paradoxically indicate worsening heart failure and poor prognosis in patients.

Keywords:

adiponectin biomarker heart failure prognosis

More Related Videos

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Experiment Videos

Last Updated: Dec 9, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Area of Science:

Endocrinology
Cardiology
Metabolic Research

Background:

Adipose tissue functions as an endocrine organ, secreting adipokines like adiponectin.
Adiponectin is also produced in the heart and offers metabolic and cardiovascular benefits.
Low adiponectin levels are linked to cardiovascular disease development.

Purpose of the Study:

To investigate the paradoxical role of adiponectin in heart failure.
To explore adiponectin as a prognostic marker for heart failure progression.

Main Methods:

Review of existing literature on adiponectin and heart failure.
Analysis of studies correlating adiponectin levels with heart failure severity and outcomes.

Main Results:

Adiponectin levels increase with heart failure severity.
Elevated adiponectin is associated with a poorer prognosis in heart failure patients.

Conclusions:

Despite its beneficial roles, elevated adiponectin signifies advanced heart failure.
Adiponectin shows potential as a predictive marker for heart failure progression and prognosis.